查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855768

BETA-內醯胺類和BETA-內醯胺酶抑制劑市場按藥物類別、給藥途徑、患者類型、應用和最終用戶分類 - 全球預測 2025-2032

Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class, Route of Administration, Patient Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，BETA-內醯胺類和BETA-內醯胺酶抑制劑市場規模將達到 425.8 億美元，複合年成長率為 4.61%。

主要市場統計數據
基準年 2024 296.8億美元
預計年份：2025年 309.8億美元
預測年份：2032年 425.8億美元
複合年成長率 (%) 4.61%

權威概述，為BETA-內醯胺類和BETA-內醯胺酶抑制劑療法的臨床重要性、科學複雜性和策略背景提供了框架。

BETA-內醯胺類抗生素及其相應的BETA-內醯胺酶抑制劑仍然是現代抗生素治療的基石，支撐著從急診護理到複雜住院患者管理的日常臨床實踐。碳青黴烯類、頭孢菌素類、單環胺基類醯胺類和青黴素類等現有藥物類別與不斷演變的抗藥性機制之間的相互作用，持續影響著治療決策、監管重點以及研發投入。過去十年，臨床醫生和政策制定者透過重新聚焦聯合治療、抗生素管理計畫以及標靶開發能夠恢復傳統BETA-內醯胺類抗生素活性的抑制劑，來應對日益嚴重的抗生素抗藥性問題。

對影響BETA-內醯胺類藥物研發和臨床應用的科學、監管、診斷和供應鏈因素進行全面分析

在科學、監管和技術力量的共同推動下，BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的治療模式正經歷一系列變革。在科學方面，化學家和生物學家正在改進抑制劑骨架，以擴大其對多種BETA-內醯胺酶的活性；轉化研究則優先開發對多重抗藥性革蘭氏陰性菌仍有效的聯合用藥方案。同時，診斷準確性也在不斷提高。快速分子檢測和以抗菌藥物管理為重點的照護現場工具使得更早停止治療和增加標靶治療方法的使用成為可能，從而改變了藥物製劑模式並影響了藥物研發的重點。

基於證據的評估，分析關稅發展和貿易政策考量如何影響抗生素產品組合的供應鏈韌性、籌資策略和商業規劃

影響貿易和關稅的政策變化可能對複雜的藥品供應鏈產生深遠影響，而圍繞2025年美國關稅的種種言論正促使相關人員重新評估採購、生產和合約安排。由於藥品原料藥和關鍵中間體通常在地理位置集中生產，關稅導致的進口成本增加和海關手續複雜化可能會波及採購預算、合約生產計劃和製造外包策略。為此，製造商和採購負責人正在考慮實現原料藥供應商的地理多元化、增加安全庫存以及將關鍵生產流程外包，以保護重要的抗生素供應免受政策波動的影響。

利用詳細的細分市場情報，將藥物類別、給藥途徑、患者群體、臨床應用和最終用戶動態聯繫起來，從而指導您的開發和商業化策略。

本研究分析了BETA-內醯胺類和BETA-內醯胺酶抑制劑領域在藥物類別、給藥途徑、患者類型、應用和最終用戶等方面的細分市場動態，以揭示不同的機會和運作需求。藥物類別包括碳青黴烯類、頭孢菌素類、單環胺基類和青黴素類。在碳青黴烯類藥物中，多利培南、厄他培南、ImipenemMeropenem等分子展現出不同的頻譜和藥物動力學特徵，這會影響醫院的製劑選擇和經驗性治療通訊協定。頭孢菌素類涵蓋第一代至第五代抗生素，對革蘭氏陰性菌和革蘭氏陽性菌的抗菌譜各不相同，這些差異對抗藥性模式和指引建議的適用性有顯著影響。青黴素類抗生素（氨基青黴素、頻譜青黴素、天然青黴素等）在社區和醫院環境中發揮重要作用，通常與標靶抑制劑合併使用作為基礎治療方案。

細緻入微的區域一體化表明，臨床實踐、監管政策、生產能力和採購模式正在塑造全球關鍵區域的策略重點。

臨床實務、法律規範、生產能力和公共衛生重點的區域差異，影響著各主要地區BETA-內醯胺類和BETA-內醯胺酶抑制劑療法的應用、開發和供應。在美洲，監管機構和臨床網路強調抗菌藥物管理、以醫院為中心的治療路徑，以及體現縮短住院時間和預防併發症價值的醫療覆蓋決策。美國仍然是後期臨床開發和先進診斷的中心，支付方越來越重視基本契約和真實世界證據。

企業策略行動和夥伴關係模式正在影響BETA-內醯胺類藥物及其互補抑制劑的開發、生產和商業化方式。

在抗生素和抑制劑領域，企業策略正圍繞著幾個長期存在的共同主題：風險共擔的合作、聚焦研發管線、產品組合最佳化以及營運韌性。創新者擴大與專業生物技術公司和受託研究機構合作，以獲取新型化學類型並分擔早期研發的成本和風險。同時，學名藥和專利到期藥物生產商正在尋求差異化製劑，例如高濃度靜脈製劑和便於患者使用的口服降劑量製劑，以最佳化生產效率並保持臨床相關性。

產業、臨床和政策領導者提出了切實可行的、有影響力的建議，以加強抗生素供應鏈、加速應用並保護治療價值。

產業、臨床和政策領導者應採取務實且多管齊下的方法，在保障抗生素可及性的同時，充分挖掘其治療和商業性價值。首先，企業應優先考慮供應鏈多元化，尋找多家原料藥和成品藥供應商，探索區域生產方案，並制定完善的庫存和緊急時應對計畫，以減輕政策和貿易相關干擾的影響。其次，調整研發組合，優先發展滿足高度未滿足臨床需求和快速分子診斷的組合療法，有助於提高藥物的普及率和醫保認可度。第三，企業應投資開發符合醫院和健保標準的真實世界證據和藥物經濟學模型，以支持報銷談判和藥物納入健保目錄。

一個透明且嚴謹的多方法研究框架，整合了臨床證據、專家訪談、監管分析和供應鏈情境測試，為策略決策提供資訊。

本分析所依據的研究採用多方法整合策略，旨在融合科學、臨床、監管和營運觀點。主要研究包括對感染疾病醫生、醫院藥劑師、法規事務專家、生產專家和供應鏈經理進行結構化訪談，以了解當地的決策和營運限制。次要研究整合了同行評審的臨床文獻、監管指導文件、臨床試驗註冊資訊和產品專論，以建構關於療效、安全性和適應症使用模式的全面證據基礎。此外，還分析了公共文件和貿易報告，以評估不斷變化的關稅和貿易政策對採購和生產策略的潛在影響。

一份簡明扼要的策略要務和前瞻性優先事項概要，摘要如何將臨床見解轉化為可操作且永續的治療成果。

抗菌藥物抗藥性壓力、診斷創新、監管演變和供應鏈重組的交匯，為BETA-內醯胺類和BETA-內醯胺酶抑制劑的研發和應用創造了一個複雜但可行的局面。治療的成功不僅取決於科學新穎性，還取決於展現實際的臨床價值、維持可靠的供應以及與抗菌藥物管理和診斷流程的無縫銜接。那些將研發重點與診斷能力結合、投資於供應鏈韌性並積極與支付方和醫療保健系統合作的機構，更有可能實現臨床獲益和永續的商業性績效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新型BETA-內醯胺酶抑制劑的出現增強了抗生素對抗藥性菌株的療效
  • BETA-內醯胺類抗生素與BETA-內醯胺酶抑制劑聯合治療的臨床應用日益增多
  • BETA-內醯胺類抗生素的進步提高了患者的遵從性和治療效果。
  • 多重病菌感染的增加推動了對BETA-內醯胺酶抑制劑的需求
  • BETA-內醯胺酶結構的研究與發展有助於標靶抑制劑的研發。
  • 整合快速診斷工具以最佳化BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的使用
  • 監管核准對加速創新BETA-內醯胺酶抑制劑上市的影響
  • 增加對標靶BETA-內醯胺類抗生素抗藥性機制的在研藥物的投資
  • 透過BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的聯合應用，向個人化醫療轉型
  • 全球抗生素管理計畫對BETA-內醯胺類抗生素和抑制劑市場動態的影響

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

  • 碳青黴烯類抗生素
    • 多利培南
    • 厄他培南
    • Imipenem
    • Meropenem
  • 頭孢菌素
    • 第五代頭孢菌素類抗生素
    • 第一代頭孢菌素
    • 第四代頭孢菌素
    • 第二代頭孢菌素
    • 第三代頭孢菌素
  • 單環胺基類
  • 青黴素
    • 氨基青黴素
    • 頻譜青黴素
    • 天然青黴素

9. 依給藥途徑分類的BETA-內醯胺類及BETA-內醯胺酶抑制劑市場

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內注射
    • 靜脈注射

10. 依患者類型分類的BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

  • 成年患者
    • 中年人
    • 老年人
    • 年輕人
  • 兒科患者
    • 青春期
    • 孩子們
    • 嬰兒
    • 新生

11. 依應用分類的BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

  • 婦科感染疾病
  • 腹腔內感染疾病
  • 術中預防
  • 呼吸道感染疾病
  • 皮膚感染疾病
    • 蜂窩性組織炎
    • 丹毒
    • 傳染性膿皰病
  • 尿道感染
    • 急性尿道感染
    • 慢性尿道感染

12. 依最終用戶分類的BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

  • 學術機構
  • 診所
  • 醫院
  • 研究所

13. 各地區BETA-內醯胺類及BETA-內醯胺酶抑制劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. BETA-內醯胺類和BETA-內醯胺酶抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國BETA-內醯胺類及BETA-內醯胺酶抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck KGaA
    • Pfizer Inc.
    • AbbVie Inc.
    • Aurobindo Pharma Limited
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • Centrient Pharmaceuticals Netherlands BV
    • Cipla Ltd.
    • Creative Diagnostics
    • F. Hoffmann-La Roche AG
    • Marubeni Corporation
    • Melinta Therapeutics, LLC
    • Novartis AG
    • Protech Telelinks
    • Qpex Biopharma, Inc. by Shionogi Inc.
    • SciClone Pharmaceuticals（Holdings）Limited
    • Sumitomo Pharma Co., Ltd.
    • Thermo Fisher Scientific Inc.
    • TOKU-E
    • Venatorx Pharmaceuticals, Inc.
    • Zai Lab Limited
Product Code: MRR-450A0628C441

The Beta Lactam & Beta Lactamase Inhibitors Market is projected to grow by USD 42.58 billion at a CAGR of 4.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 29.68 billion
Estimated Year [2025] USD 30.98 billion
Forecast Year [2032] USD 42.58 billion
CAGR (%) 4.61%

An authoritative overview framing the clinical importance, scientific complexity, and strategic context of beta-lactam and beta-lactamase inhibitor therapeutics

Beta-lactam antibiotics and their companion beta-lactamase inhibitors remain foundational pillars of modern antimicrobial therapy, underpinning routine clinical practice from emergency care to complex inpatient management. The interplay between established drug classes such as carbapenems, cephalosporins, monobactams, and penicillins and evolving resistance mechanisms continues to shape therapeutic decision-making, regulatory priorities, and R&D investment. Over the past decade, clinicians and policy makers have responded to rising antimicrobial resistance with renewed emphasis on combination therapies, stewardship programs, and targeted development of inhibitors that restore the activity of legacy beta-lactams.

Concurrently, advances in molecular diagnostics, pharmacokinetics, and formulation science have refined how these agents are deployed across diverse patient populations and clinical settings. These technical and operational shifts are not discrete; they coalesce into a complex environment where scientific innovation must align with supply chain resilience, reimbursement structures, and public health imperatives. Against this backdrop, stakeholders require clear, actionable intelligence that synthesizes clinical evidence, regulatory signals, and system-level dynamics to inform product strategies, clinical development plans, and market access pathways. This report provides that structured perspective and equips decision-makers with the context necessary to navigate both persistent challenges and emerging opportunities.

A synthesized analysis of the scientific, regulatory, diagnostic, and supply chain forces reshaping the development and clinical deployment of beta-lactam-based therapies

The therapeutic landscape for beta-lactams and beta-lactamase inhibitors is undergoing a sequence of transformative shifts driven by scientific, regulatory, and technological forces. On the scientific front, chemists and biologists have refined inhibitor scaffolds to broaden activity against diverse beta-lactamases, while translational research has prioritized combinations that preserve efficacy against multidrug-resistant Gram-negative organisms. These advances are running in parallel with improvements in diagnostic precision: rapid molecular assays and stewardship-focused point-of-care tools are enabling earlier de-escalation or targeted escalation of therapy, thereby changing prescribing patterns and influencing drug development priorities.

Regulatory and payer environments are also evolving, with accelerated approval pathways and value-based contracting models encouraging innovation that demonstrably improves clinical outcomes or reduces hospital resource utilization. Manufacturing and supply chain strategies have shifted from cost-centric to resilience-centric models, catalyzed by global disruptions that highlighted the risks of concentrated production footprints. Finally, cross-sector collaboration among academia, biotech innovators, and larger pharmaceutical firms has become more common, enabling shared risk for difficult-to-develop molecules while leveraging complementary capabilities. Together, these shifts are enabling a more nuanced approach to antibiotic stewardship, clinical deployment, and commercial strategy that balances efficacy, access, and sustainability.

An evidence-based appraisal of how tariff dynamics and trade policy considerations are influencing supply chain resilience, sourcing strategies, and commercial planning for antibiotic portfolios

Policy shifts affecting trade and tariffs can exert outsized effects on complex pharmaceutical supply chains, and the discourse around United States tariffs in 2025 has prompted stakeholders to re-evaluate sourcing, manufacturing, and contractual arrangements. Pharmaceutical active pharmaceutical ingredients and key intermediates are often produced in geographically concentrated clusters; any tariff-driven increase in import costs or customs complexity can ripple through procurement budgets, contract manufacturing timelines, and inventory strategies. In response, manufacturers and purchasers have been exploring greater geographic diversification of API suppliers, increased safety stock, and nearshoring of critical production steps to insulate essential antibiotic supply from policy volatility.

Beyond direct cost implications, tariff dynamics influence strategic investment decisions. Developers weighing late-stage trials or scaling production may adjust timelines or negotiate alternate supply agreements to preserve margins and delivery reliability. Health systems and payers may respond by tightening sourcing criteria or prioritizing suppliers with demonstrable supply continuity. At the same time, tariffs can accelerate domestic capacity-building initiatives as governments and industry seek to reduce strategic dependence on single-source geographies; those initiatives include incentives for manufacturing upgrades, streamlined regulatory support for facility qualification, and public-private partnerships. Taken together, the cumulative impact of tariff policy considerations in 2025 and beyond has been to sharpen focus on supply chain resilience, to encourage investment in diversified manufacturing footprints, and to elevate contractual and operational risk management as core components of commercial planning.

In-depth segmentation intelligence linking drug class, administration route, patient demographics, clinical applications, and end-user dynamics to inform development and commercialization strategy

Segment-level dynamics within the beta-lactam and beta-lactamase inhibitor space reveal differentiated opportunities and operational imperatives when analyzed across drug class, route of administration, patient type, application, and end user. Drug class segmentation encompasses carbapenems, cephalosporins, monobactam, and penicillins. Within carbapenems, distinct molecules such as doripenem, ertapenem, imipenem, and meropenem exhibit varied spectrum and pharmacokinetic profiles that influence hospital formulary decisions and empirical therapy protocols. Cephalosporins span first- through fifth-generation agents with differing Gram-negative and Gram-positive coverage, and these generational differences meaningfully affect positioning relative to resistance patterns and guideline recommendations. Penicillins, including aminopenicillins, extended-spectrum penicillins, and natural penicillins, retain key roles across community and hospital settings and often serve as backbone agents when coupled with targeted inhibitors.

Route-of-administration segmentation separates oral administration and parenteral administration. Oral options, delivered as capsules or tablets, support outpatient stewardship strategies, step-down therapy, and continuity of care post-discharge, while parenteral administration via intramuscular or intravenous routes remains essential for severe infections and inpatient management. Patient-type segmentation distinguishes adult and pediatric populations, with adults further stratified into young, middle-aged, and senior cohorts and pediatric classification including adolescents, children, infants, and neonates; each demographic subgroup presents unique pharmacokinetic considerations, dosing strategies, and safety profiles that affect clinical development and labeling decisions. Application-based segmentation covers gynecological, intra-abdominal, intraoperative prophylaxis, respiratory, skin, and urinary tract infections; skin indications further break down into cellulitis, erysipelas, and impetigo, and urinary tract infections distinguish acute from chronic presentations. These clinical use-cases drive differentiation in formulation, duration of therapy, and evidence generation needs. Finally, end-user segmentation includes academic institutions, clinics, hospitals, and research laboratories, each with distinct procurement cycles, clinical governance frameworks, and evidence thresholds for adopting new combinations or formulations. Understanding these layered segments enables developers and commercial teams to align clinical trials, regulatory strategies, and go-to-market plans with the nuanced requirements of prescribers, payers, and institutional buyers.

A nuanced regional synthesis showing how clinical practice, regulatory policy, manufacturing capacity, and procurement models shape strategic priorities across major global geographies

Regional variation in clinical practice, regulatory frameworks, manufacturing capacity, and public health priorities shapes the adoption, development, and supply of beta-lactam and beta-lactamase inhibitor therapies across major geographies. In the Americas, regulatory authorities and clinical networks place strong emphasis on antimicrobial stewardship, hospital-centric treatment pathways, and coverage decisions that reflect value in reducing length of stay and preventing complications. The United States remains a hub for late-stage clinical development and advanced diagnostics, with payers increasingly focused on outcomes-based contracting and real-world evidence to inform reimbursement.

Europe, Middle East & Africa present a heterogeneous landscape where national-level procurement practices, variable access to diagnostics, and differing reimbursement models lead to distinct regional strategies. Several European countries emphasize centralized procurement and tight stewardship protocols, while some Middle East and African markets prioritize access and capacity-building, creating avenues for tailored access programs and tiered pricing arrangements. Asia-Pacific combines dynamic demand with concentrated manufacturing capabilities and regulatory modernization. Several markets in Asia-Pacific have become major production centers for APIs and finished formulations, while others are substantial demand centers owing to high infectious disease burden and growing healthcare infrastructure investment. Regional regulatory harmonization efforts, clinical trial site availability, and local manufacturing incentives all play roles in shaping how companies prioritize launches, scale production, and structure distribution networks. Cross-regional strategies that account for these differences in clinical practice, policy environment, and industrial capability will be essential for effective global deployment of new therapeutic combinations and stewardship-aligned access models.

Strategic corporate behaviors and partnership models that are shaping how organizations develop, manufacture, and commercialize beta-lactam therapies and complementary inhibitors

Company strategies in the antibiotic and inhibitor domain are coalescing around several enduring themes: risk-sharing collaborations, focused pipelines, portfolio optimization, and operational resilience. Innovator organizations are increasingly partnering with specialized biotech firms or contract research organizations to access novel chemotypes and to share the costs and risks of early development. Simultaneously, generics and off-patent manufacturers are optimizing production efficiency and pursuing differentiated formulations, such as high-concentration intravenous presentations or patient-friendly oral step-down options, to maintain clinical relevance.

Across the competitive landscape, firms are prioritizing assets that address high unmet clinical need or that restore activity to existing beta-lactams in the face of specific resistance mechanisms. Licensing agreements and co-development partnerships enable speed-to-market while spreading technical risk, and companies are investing in manufacturing flexibility to adapt to regional demand and policy shifts. Contract manufacturing organizations and research laboratories play pivotal roles in scaling production and supporting complex analytical validation. Moreover, firms are increasingly integrating real-world evidence generation and health-economic modeling into development plans to support reimbursement negotiations and to demonstrate comparative value to payers and hospital procurement committees. Taken together, these strategic behaviors underscore a sector moving toward more collaborative, evidence-driven, and operationally resilient models of product development and commercialization.

Practical and high-impact recommendations for industry, clinical, and policy leaders to strengthen supply chains, accelerate adoption, and safeguard therapeutic value in antibiotics

Leaders across industry, clinical practice, and policy should adopt a pragmatic, multi-dimensional approach to capture therapeutic and commercial value while safeguarding access. First, organizations should prioritize supply chain diversification by qualifying multiple API and finished-dosage form suppliers, exploring regional manufacturing options, and implementing robust inventory and contingency planning to mitigate policy or trade-related disruptions. Second, aligning R&D portfolios to prioritize combinations that demonstrably address high clinical unmet need and that are compatible with rapid molecular diagnostics will enhance adoption and payer receptivity. Third, companies should invest in early generation of real-world evidence and pharmacoeconomic models tailored to hospital and payer decision criteria to support reimbursement discussions and formulary inclusion.

Fourth, forging partnerships with diagnostic developers, health systems, and stewardship coalitions will improve appropriate use and strengthen clinical value propositions. Fifth, engage proactively with regulatory agencies to explore streamlined pathways and adaptive trial designs that can accelerate access for high-need indications while maintaining rigorous safety and efficacy standards. Sixth, develop tailored regional access plans that account for local formularies, procurement mechanisms, and capacity constraints, leveraging tiered pricing or managed entry agreements where appropriate. Finally, embed antimicrobial stewardship principles into commercial strategies to ensure long-term efficacy and societal value of new therapeutic combinations. These coordinated actions will help organizations balance near-term commercial imperatives with the broader public health mandate to preserve antibiotic effectiveness.

A transparent and rigorous multi-method research framework integrating clinical evidence, expert interviews, regulatory analysis, and supply chain scenario testing to inform strategic decisions

The research underpinning this analysis draws on a multi-method approach designed to integrate scientific, clinical, regulatory, and operational perspectives. Primary research included structured interviews with infectious disease clinicians, hospital pharmacists, regulatory affairs experts, manufacturing specialists, and supply chain managers to capture frontline decision-making and operational constraints. Secondary research synthesized peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and product monographs to build a comprehensive evidence base on efficacy, safety, and indication-specific use patterns. In addition, public policy documents and trade reports were analyzed to assess potential impacts of tariff and trade policy developments on procurement and manufacturing strategies.

Supply chain mapping exercises and scenario-based stress tests were employed to identify vulnerabilities and mitigation levers across sourcing, production, and distribution. Health technology assessment frameworks and pharmacoeconomic modeling informed the evaluation of payer-relevant value drivers without producing quantitative market estimations. Where appropriate, cross-validation with expert panels ensured that conclusions reflect clinical reality and operational feasibility. This convergent methodology supports robust qualitative insights while preserving transparency about data sources and analytical assumptions.

A concise synthesis of strategic imperatives and forward-looking priorities that summarize how to translate clinical insight into operational readiness and sustainable therapeutic impact

The convergence of antimicrobial resistance pressures, diagnostic innovation, regulatory evolution, and supply chain recalibration has created a complex but navigable landscape for beta-lactam and beta-lactamase inhibitor development and deployment. Therapeutic success will depend not only on scientific novelty but also on the ability to demonstrate actionable clinical value, maintain reliable supply, and integrate seamlessly with stewardship and diagnostic workflows. Organizations that align R&D priorities with diagnostic capabilities, that invest in supply chain resilience, and that engage proactively with payers and health systems will be positioned to deliver both clinical benefit and sustainable commercial performance.

Looking ahead, the sector is likely to favor pragmatic innovation that restores or extends the utility of established beta-lactams while minimizing collateral selection pressure and preserving access. Collaborative models that distribute risk and leverage complementary competencies will remain central to advancing novel inhibitors into practice. Ultimately, stakeholders who translate deep clinical insight into operational readiness and evidence-aligned value propositions can simultaneously advance patient outcomes and create durable strategic advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel beta lactamase inhibitors enhancing antibiotic efficacy against resistant strains
  • 5.2. Increasing adoption of combination therapies involving beta lactam antibiotics and inhibitors in clinical settings
  • 5.3. Advancements in beta lactam antibiotic formulations improving patient compliance and therapeutic outcomes
  • 5.4. Rising prevalence of multidrug-resistant bacterial infections driving demand for beta lactamase inhibitors
  • 5.5. Expansion of research in beta lactamase enzyme structure aiding development of targeted inhibitors
  • 5.6. Integration of rapid diagnostic tools to optimize beta lactam and beta lactamase inhibitor usage
  • 5.7. Impact of regulatory approvals accelerating availability of innovative beta lactamase inhibitor drugs
  • 5.8. Growing investment in pharmaceutical pipelines targeting beta lactam antibiotic resistance mechanisms
  • 5.9. Shift towards personalized medicine approaches utilizing beta lactam and beta lactamase inhibitor combinations
  • 5.10. Influence of global antimicrobial stewardship programs on beta lactam and inhibitor market dynamics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

  • 8.1. Carbapenems
    • 8.1.1. Doripenem
    • 8.1.2. Ertapenem
    • 8.1.3. Imipenem
    • 8.1.4. Meropenem
  • 8.2. Cephalosporins
    • 8.2.1. Fifth-Generation Cephalosporins
    • 8.2.2. First-Generation Cephalosporins
    • 8.2.3. Fourth-Generation Cephalosporins
    • 8.2.4. Second-Generation Cephalosporins
    • 8.2.5. Third-Generation Cephalosporins
  • 8.3. Monobactam
  • 8.4. Penicillins
    • 8.4.1. Aminopenicillins
    • 8.4.2. Extended-Spectrum Penicillins
    • 8.4.3. Natural Penicillins

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous

10. Beta Lactam & Beta Lactamase Inhibitors Market, by Patient Type

  • 10.1. Adult Patients
    • 10.1.1. Middle-Aged Adults
    • 10.1.2. Senior Adults
    • 10.1.3. Young Adults
  • 10.2. Pediatric Patients
    • 10.2.1. Adolescents
    • 10.2.2. Children
    • 10.2.3. Infants
    • 10.2.4. Neonates

11. Beta Lactam & Beta Lactamase Inhibitors Market, by Application

  • 11.1. Gynecological Infections
  • 11.2. Intrabdominal Infections
  • 11.3. Intraoperative Prophylaxis
  • 11.4. Respiratory Infections
  • 11.5. Skin Infections
    • 11.5.1. Cellulitis
    • 11.5.2. Erysipelas
    • 11.5.3. Impetigo
  • 11.6. Urinary Tract Infections
    • 11.6.1. Acute UTI
    • 11.6.2. Chronic UTI

12. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Clinics
  • 12.3. Hospitals
  • 12.4. Research Laboratories

13. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Beta Lactam & Beta Lactamase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Beta Lactam & Beta Lactamase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck KGaA
    • 16.3.2. Pfizer Inc.
    • 16.3.3. AbbVie Inc.
    • 16.3.4. Aurobindo Pharma Limited
    • 16.3.5. Bio-Rad Laboratories, Inc.
    • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.7. Centrient Pharmaceuticals Netherlands B.V.
    • 16.3.8. Cipla Ltd.
    • 16.3.9. Creative Diagnostics
    • 16.3.10. F. Hoffmann-La Roche AG
    • 16.3.11. Marubeni Corporation
    • 16.3.12. Melinta Therapeutics, LLC
    • 16.3.13. Novartis AG
    • 16.3.14. Protech Telelinks
    • 16.3.15. Qpex Biopharma, Inc. by Shionogi Inc.
    • 16.3.16. SciClone Pharmaceuticals (Holdings) Limited
    • 16.3.17. Sumitomo Pharma Co., Ltd.
    • 16.3.18. Thermo Fisher Scientific Inc.
    • 16.3.19. TOKU-E
    • 16.3.20. Venatorx Pharmaceuticals, Inc.
    • 16.3.21. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY COUNTRY, 2025-2032 (USD MILLION)

TABLE